The $50 billion Rural Health Transformation Fund, tied to the working families tax cut legislation, will be fully disbursed to state governors by the end of the calendar year.
“$50 billion the largest investment ever made in rural healthcare through our agency was given up by the end of the calendar year. All the governors have the money and we charge them to make a difference in their communities.”
View on YouTube
Explanation
The Rural Health Transformation Program distributes $10 billion annually from 2026-2030, not the full $50 billion in one calendar year; first-year 2026 state awards averaged only about $200 million per state.
AI-supported robots will begin performing ultrasounds in rural parts of Alabama lacking OB-GYN providers, and drones will deliver prescription medications to Alaska's North Slope where roads don't exist, funded by the rural health investment.
“We have AI supported robots that are going to be doing ultrasounds in parts of Alabama where there are no OBS... We have drones delivering prescription medications to the North Slope of Alaska, where there are no roads.”
View on YouTube
Explanation
No specific public reporting found confirming or denying AI-supported ultrasound robots in rural Alabama or drone prescription delivery to Alaska's North Slope under this program.
GLP-1 weight-loss drug cash prices will drop from roughly $1,200 to a starting price of about $200 for injections and $150 for pills, with the first FDA-approved pill versions becoming available this month.
“It's going to be a starting price of around $200. And with the pills, it's $150 and the pills will come out. Uh the first FDA approved pills will start this month.”
View on YouTube
Explanation
The oral-pill starting price of about $150 roughly matched, but the injectable cash price landed near $245, not the predicted $200; a partial match on pricing terms.
Within two years of the lowered GLP-1 pricing taking effect, reduced spending on downstream chronic illnesses (hypertension, diabetes, and related conditions) will net-positive return money to the American taxpayer.
“At that price day... we will within two years return money to the American taxpayer. It's going to save us so much money from reducing hypertension, diabetes, and the downstream illnesses.”
View on YouTube
Explanation
The predicted two-year payback horizon for downstream healthcare savings has not yet elapsed since the pricing deal.
The Trump administration will launch "Trump Rx" the following week, offering GLP-1 drugs from Novo Nordisk and Eli Lilly at agreed lower cash-pay prices, with a $50 copay for Medicare patients and no out-of-pocket cost for Medicaid patients.
“So we agreed to those prices with the two major companies Novo Nordisk and Eli Lilly. We will launch next week Trump RX with those products so you can cash pay at a price that is completely affordable... Every Medicare patient gets it for $50 co-pay. Every Medicaid patient gets it for nothing.”
View on YouTube
Explanation
The predicted pricing terms (Medicare $50 copay, free for Medicaid) materialized largely as described, but the launch did not happen "next week" -- the Medicare GLP-1 Bridge program actually launched July 1, 2026, months later.